Show results for
drug-discovery-and-design-platform Videos
3 videos found
We use our proprietary drug discovery platform, OdyssION™, to discover novel medicines against intractable or inadequately drugged targets. In this video, we describe what makes our platform ...
Jun. 12, 2022
How is STALICLA categorizing subgroups of patients with Autism? STALICLA leverages on its proprietary drug-discovery platform to bring personalized medicine to patients with autism and other ill-defined NDDs. This platform is called called DEPI: Databased Endophenotyping Patient Identification. DEPI analyses vast amounts of anonymized data from large cohorts of patients with ASD, including ...
Feb. 22, 2022
BySTALICLA
Modern drug discovery is inefficient, expensive and risky. On average, there are 2000 failed compounds sitting on pharmaceutical companies shelves, and this number grows at the rate 200 drugs per year. Furthermore, the average costs of a successful drug introduction is a staggering $3bln with an average time-to-market of more than 10 years. This is due to extensive discovery costs including: R&D, ...
Apr. 16, 2021